Amylyx Pharmaceuticals opened lower at $31.43, compared with its previous close of $31.80. In the last trading session, the stock traded between $30.10 and $31.57. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Amylyx Pharmaceuticals is now worth
$ 165.29
Giving a profit of
$ 65.29 (65.29%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
$-1.93 (-6.08%)
Day High
$31.57
Day Low
$30.10
Day Open
$31.43
Prev Close
$31.80
Volume
12,21,060
1W Return
1.61%
1M Return
8.72%
3M Return
26.43%
6M Return
100.73%
1Y Return
135.55%
Market Cap ($ Mn)
3,840
PE Ratio
-
PB Ratio
16.18
PEG Ratio
-
ROE
-61.78%
ROCE
-64.86%
EPS (TTM)
$-0.35
1 Week
1.61%
1 Month
8.72%
3 Months
26.43%
6 Months
100.73%
9 Months
108.14%
Mizuho maintains Outperform on Amylyx, raises price target to $39
Mizuho maintains Outperform rating on Amylyx Pharmaceuticals. Price target raised from $38 to $39 by analyst Graig Suvannavejh. Rating status remains unchanged despite the target increase.
2 days agoAmylyx reports positive Phase 3 data, raises $544.6M net proceeds
Phase 3 LUCIDITY trial showed 55% reduction in hypoglycemic events vs placebo. Net proceeds from upsized public offering reached approximately $544.6 million. Cash position rose to $768.1 million as of September 30, 2026. Net loss widened to $45.5 million from $34.4 million in Q3 2025. NDA submission for avexitide remains on track for end of 2026.
7 days agoAmylyx Pharma to present Phase 3 Avexitide data at ObesityWeek 2026
Amylyx Pharmaceuticals will present Phase 3 LUCIDITY trial topline results for Avexitide at ObesityWeek 2026 in November. The late-breaking oral presentation follows positive topline results announced in August 2026 for post-bariatric hypoglycemia. A second presentation will detail machine learning methods to identify PBH patients using real-world claims data. Q2FY26 cash and marketable securities stood at $250.8 million, providing a cash runway into 2028.
1mo agoAmylyx prices upsized $500 million public stock offering at $35.50
Amylyx Pharmaceuticals priced an upsized public offering of 14,090,000 shares at $35.50 per share, raising $500.2 million. The company granted a 30-day over-allotment option for 2,113,500 additional shares. Proceeds will support avexitide pre-commercial activities and R&D. The offering closes around August 21, 2026, managed by Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital.
2mo agoMizuho raises Amylyx Pharmaceuticals price target to $42 on Outperform
Mizuho analyst Graig Suvannavejh maintains an Outperform rating on Amylyx Pharmaceuticals (NASDAQ: AMLX). The firm raised its price target from $30 to $42, signaling increased confidence in the stock's potential.
2mo agoAmylyx LUCIDITY trial meets endpoint, shares rise 35%
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) reported positive Phase 3 LUCIDITY trial results for avexitide, meeting the primary endpoint with a 55% reduction in hypoglycemic events. Shares surged 35.32% to $29.01. The company plans an NDA filing by late 2026 and holds $250.8 million in cash.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Amylyx Pharmaceuticals is now worth
$ 165.29
Giving a profit of
$ 65.29 (65.29%)
Note: Past profits do not guarantee future returns.
